全文获取类型
收费全文 | 61467篇 |
免费 | 5859篇 |
国内免费 | 4661篇 |
专业分类
耳鼻咽喉 | 425篇 |
儿科学 | 693篇 |
妇产科学 | 554篇 |
基础医学 | 6670篇 |
口腔科学 | 1010篇 |
临床医学 | 8291篇 |
内科学 | 8634篇 |
皮肤病学 | 648篇 |
神经病学 | 3168篇 |
特种医学 | 2429篇 |
外国民族医学 | 30篇 |
外科学 | 6464篇 |
综合类 | 11151篇 |
现状与发展 | 11篇 |
一般理论 | 3篇 |
预防医学 | 4084篇 |
眼科学 | 1881篇 |
药学 | 6832篇 |
50篇 | |
中国医学 | 3972篇 |
肿瘤学 | 4987篇 |
出版年
2024年 | 210篇 |
2023年 | 986篇 |
2022年 | 2477篇 |
2021年 | 3028篇 |
2020年 | 2441篇 |
2019年 | 2187篇 |
2018年 | 2052篇 |
2017年 | 2054篇 |
2016年 | 1881篇 |
2015年 | 2851篇 |
2014年 | 3463篇 |
2013年 | 3114篇 |
2012年 | 4603篇 |
2011年 | 5006篇 |
2010年 | 3381篇 |
2009年 | 2765篇 |
2008年 | 3361篇 |
2007年 | 3303篇 |
2006年 | 3191篇 |
2005年 | 3235篇 |
2004年 | 2232篇 |
2003年 | 2204篇 |
2002年 | 2004篇 |
2001年 | 1598篇 |
2000年 | 1358篇 |
1999年 | 1301篇 |
1998年 | 857篇 |
1997年 | 782篇 |
1996年 | 613篇 |
1995年 | 556篇 |
1994年 | 471篇 |
1993年 | 330篇 |
1992年 | 371篇 |
1991年 | 328篇 |
1990年 | 298篇 |
1989年 | 213篇 |
1988年 | 211篇 |
1987年 | 162篇 |
1986年 | 147篇 |
1985年 | 104篇 |
1984年 | 54篇 |
1983年 | 48篇 |
1982年 | 21篇 |
1981年 | 27篇 |
1980年 | 15篇 |
1979年 | 21篇 |
1978年 | 8篇 |
1976年 | 7篇 |
1973年 | 6篇 |
1971年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
1.
2.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis 下载免费PDF全文
3.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
4.
Dan-Feng Xu Bing Wu Jin-Xin Wang Jian Yu Jian-Xin Xie 《World Journal of Clinical Cases》2021,9(5):1096-1102
BACKGROUNDGuillain-Barré syndrome (GBS) is a rare disorder that typically presents with ascending weakness, pain, paraesthesias, and numbness, which mimic the findings in lumbar spinal stenosis. Here, we report a case of severe lumbar spinal stenosis combined with GBS.CASE SUMMARYA 70-year-old man with a history of lumbar spinal stenosis presented to our emergency department with severe lower back pain and lower extremity numbness. Magnetic resonance imaging confirmed the diagnosis of severe lumbar spinal stenosis. However, his symptoms did not improve postoperatively and he developed dysphagia and upper extremity numbness. An electromyogram was performed. Based on his symptoms, physical examination, and electromyogram, he was diagnosed with GBS. After 5 d of intravenous immunoglobulin (0.4 g/kg/d for 5 d) therapy, he gained 4/5 of strength in his upper and lower extremities and denied paraesthesias. He had regained 5/5 of strength in his extremities when he was discharged and had no symptoms during follow-up.CONCLUSIONGBS should be considered in the differential diagnosis of spinal disorder, even though magnetic resonance imaging shows severe lumbar spinal stenosis. This case highlights the importance of a careful diagnosis when a patient has a history of a disease and comes to the hospital with the same or similar symptoms. 相似文献
5.
目前新型冠状病毒肺炎(COVID-19)疫情在全球蔓延,形势严峻,并对全球公共卫生事业构成巨大挑战,快速准确的诊断COVID-19对疫情的防控有重要意义。本文报道1例COVID-19患者的调查和确诊过程,以对COVID-19确诊和疫情防控提供有价值的参考。患者为赴渝务工于2020年1月23日返乡人员,在渝期间,其同工地的一同事确诊为COVID-19,之后该工地接连有另外8位同事被确诊。患者返乡后2月2日被当地疫情防控单位采取医学隔离。患者于隔离后不久出现咳嗽,阵发性,干咳为主,偶可咳出黄色痰液等COVID-19相关临床症状,遂被当地新型冠状病毒肺炎定点医疗单位收治,后经市级新型冠状病毒肺炎诊治专家组远程视频会诊转入四川大学华西医院资阳医院。患者先后经历9次核酸检测,在前8次核酸检测均为阴性的情况下,于第9次核酸检测结果为阳性,2月21日最终确诊为新型冠状病毒肺炎。 相似文献
6.
7.
8.
9.
Yuan Peng Yuman Li Haiyan Cao Liu Hong Yu Wang Mingxing Xie 《Journal of ultrasound in medicine》2019,38(2):539-544
A pulmonary artery (PA) sling is a very rare congenital cardiovascular anomaly, and only a few studies have reported PA slings in fetuses. The relationship of the PA, aorta, ductus arteriosus, and trachea can be evaluated in the 3‐vessel and 3‐vessel and trachea views during fetal echocardiography. A PA sling can be detected by abnormal positioning of the left PA in relation to the trachea when sweeping from the 3‐vessel view cranially to the 3‐vessel and trachea view. Here we report 3 cases of fetal PA slings and their follow‐ups. Two cases were confirmed by postnatal echocardiography, and the other case was confirmed by a cardiovascular cast after pregnancy termination. We emphasize that the 3‐vessel and 3‐vessel and trachea views are of crucial importance in the prenatal diagnosis of a PA sling. 相似文献
10.
Xia Li Wang Junni Xie Xishao Xiang Shilong Zhang Xiaohui Chen Jianghua Han Fei 《中华肾脏病杂志》2020,36(7):497-502
Objective To observe the clinical characteristics and prognosis of patients with rapidly progressive glomerulonephritis (RPGN) caused by lupus nephritis, antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, or primary glomerulonephritis who were treated with peritoneal dialysis (PD) and then withdrew PD because of renal recovery. Methods Data of the above patients were retrospectively analyzed. The patients were diagnosed as RPGN and received PD therapy in Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University from February 2009 to August 2018. The patients were divided into early withdrawal group (PD time≤183 days, n=24) and late withdrawal group (PD time>183 day, n=24). The differences of clinical characteristics between the two groups were compared. The cumulative incidence of adverse events in both groups was analyzed using Kaplan-Meier curves. Cox proportional hazards model was used to analyze the risk factors influencing the prognosis of patients. Results Forty-eight RPGN patients were included. The median time of maintaining PD was 178(76, 378) days. Compared with the late withdrawal group, the patients in early withdrawal group had lower levels of urine volume, serum albumin and parathyroid hormone, and lower rates of gross hematuria and hypertension at the beginning of PD, and received higher rates of methylprednisolone impulse, combined immunosuppressive agents, and hemodialysis or continuous renal replacement therapy (all P<0.05). At the time of PD withdrawal, the levels of serum creatinine, serum calcium, serum albumin and parathyroid hormone in the early withdrawal group were significantly lower than those in the late withdrawal group (all P<0.05). The Kaplan-Meier curves showed that there was no significant difference in the cumulative survival of patients in both groups (log-rank test χ2=3.485, P=0.062). Cox regression analysis revealed serum creatinine≥209 μmol/L at the time of PD withdrawal was an independent risk factor for poor prognosis (HR=5.253,95%CI 1.757-15.702, P=0.003). Conclusions PD can be used for RPGN patients caused by lupus nephritis, ANCA-associated vasculitis and primary nephritis. Serum creatinine≥209 μmol/L at the time of PD withdrawal is an independent risk factor for poor prognosis. 相似文献